Overview

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Status:
Not yet recruiting

Trial end date:
2026-01-30

Target enrollment:

Participant gender:

Summary

The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Fulvestrant